Rein Therapeutics
Market cap $30.7M 86.3M shares (10-Q, Nov 12, 2026) × $0.356 close Nov 17, 2026
Most recent annual filing: 2026-03-26
- admilparant BMS Ph3 topline2H 2026admilparant BMS Ph3 topline, 2H 2026, material
- LTI-03 Ph2 interim4Q 2026LTI-03 Ph2 interim, 4Q 2026, notable
- LTI-03 topline2027LTI-03 topline, 2027, thesis-defining
- RENEW enrollment doneEarly 2027RENEW enrollment done, Early 2027, notable
- RNTX listing updateFeb 17, 2027RNTX listing update, Feb 17, 2027, routine
- Tyvaso nebulized PDUFA dateApr 2027Tyvaso nebulized PDUFA date, Apr 2027, material
- TETON-1/-2 United Therapeutics PDUFA dateApr 2027TETON-1/-2 United Therapeutics PDUFA date, Apr 2027, material
- ASPIRE Vicore Ph2b toplineMid-2027ASPIRE Vicore Ph2b topline, Mid-2027, material
- RNTX legacy warrants corporate updateMay 2027RNTX legacy warrants corporate update, May 2027, routine
- MIST Avalyn Ph2b topline2H 2027MIST Avalyn Ph2b topline, 2H 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (1 active programs)
Discontinued (2)
- LTI-01 — Loculated Pleural Effusion · suspended development for an indefinite period due to capital limitations; allocating limited resources to LTI-03
- LTI-05 — Cystic Fibrosis · suspended development activities for preclinical programs for an indefinite period due to capital limitations
Capital (as filed)
- Cash
- $943K cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $35.5M Sep 30, 2026
- Long-term investments
- $994K Sep 30, 2026
- Operating cash flow
- −$7.3M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $36.5M cash, runway first quarter of 2028 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (2)
- 2026-11-17 UPDATE: Rein Therapeutics (RNTX) - The Interim That Couldn’t Speak 🔒 Paid
- 2026-09-09 Rein Therapeutics (RNTX) — Scientific Deep Dive for LTI-03 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (2 calls)
Every verdict Biotech Distilled has published on Rein Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-09-09 Watch Rein Therapeutics (RNTX) — Scientific Deep Dive for LTI-03 and Pipeline Products Biology is real but the differentiating epithelial-regeneration mechanism has no significant human evidence, disclosure is selectively framed, and the Q4 2026 interim is arithmetically incapable of informing efficacy.
- 2026-11-17 Watch UPDATE: Rein Therapeutics (RNTX) - The Interim That Couldn't Speak Interim was blinded and uninformative on efficacy, but faster-than-expected enrollment pulls the real binary into 2027; drug is near cash value but reverse split and post-topline raise both look likely, so it stays on the watch list rather than a buy.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“We expect to report initial interim data on some proportion of patients in the fourth quarter of 2026.”
matched to LTI-03 · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (17)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Nov 2, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026ReleaseRein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Resu→ BD updateSummary on the 8-K
- Nov 16, 20268-KCurrent report: other events · EX-99.1→ BD updateThe Q4 2026 RENEW interim I called a "coin flip dressed as a signal" just landed — blinded, pooled, n=24, no treatment-arm comparison possible — and the stock dropped 27.5% in today's session on data that cannot, by design, tell us whether LTI-03 works.
- Nov 16, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 2, 2026ReleaseRein Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
- Sep 4, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Aug 27, 20268-KCurrent report: listing notice
- Aug 14, 202610-QQuarterly report
- Jul 21, 20268-KCurrent report: shareholder vote
- Jun 8, 2026DEFA14AProxy soliciting material
- Jun 8, 2026DEF 14AProxy statement
- May 15, 202610-QQuarterly report
- May 4, 20268-KCurrent report: material agreement, other events · EX-99.1
- May 4, 2026424B5Prospectus supplement (offering)
- Apr 28, 2026S-1Registration statement
- Apr 27, 202610-K/AAnnual report (amended)
- Mar 26, 202610-KAnnual report
- Mar 2, 20268-KCurrent report: material agreement, debt / obligation, unregistered sale of equity
13 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 13, 2026SCHEDULE 13G/A13G amendment
- Jul 14, 2026SCHEDULE 13G/A13G amendment
- Jun 8, 2026ARSAnnual report to shareholders
- May 28, 2026PRE 14APRE 14A
- May 8, 2026SCHEDULE 13G/A13G amendment
- May 8, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 7, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 6, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 30, 2026EFFECTRegistration effective
- Apr 28, 2026CORRESPCORRESP
- Apr 28, 2026CORRESPCORRESP